Advertisement

Vitiligo

  • Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka
Chapter

Abstract

Vitiligo is a cutaneous disorder of depigmentation that occurs due to autoimmune destruction of the skin’s pigment-producing melanocytes. The exact cause is unknown and thought to be influenced by multiple genes and environment factors. Vitiligo is characterized by chalk-white macules that show uniform loss of pigment of the affected skin and hair (leukotrichia). There is an association between vitiligo and other autoimmune disorders, such as diabetes, Addison’s disease, and autoimmune thyroiditis. Treatment of vitiligo concentrates on modifying the body’s immune response. This is achieved primarily with topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and phototherapy.

Keywords

Vitiligo Idiopathic Depigmentation Hypopigmentation Generalized Segmental Non-segmental Autoimmune Diabetes Addison’s disease Hypothyroid Hyperthyroid Macules Leukotrichia Repigmentation Phototherapy Vitamin D analogues Calcipotriene Calcineurin inhibitors Topical corticosteroids Melanin Ultraviolet light 

References

  1. 1.
    Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. pii: S0140-6736(14)60763-7.CrossRefPubMedGoogle Scholar
  2. 2.
    Birlea SA, Spritz RA, Norris DA. Chapter 74. Vitiligo. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. Available from: http://accessmedicine.mhmedical.com.ezproxy.cul.columbia.edu/content.aspx?bookid=392&Sectionid=41138776. Accessed 26 Feb 2015.Google Scholar
  3. 3.
    Taïeb A, Picardo M. Vitiligo. N Engl J Med. 2009;360(2):160.CrossRefPubMedGoogle Scholar
  4. 4.
    Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;2, CD003263.Google Scholar
  5. 5.
    Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitiligo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med. 2011;11:21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Whitton ME, Ashcroft DM, González U. Therapeutic interventions for vitiligo. J Am Acad Dermatol. 2008;59(4):713–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008;74(4):357–60.CrossRefPubMedGoogle Scholar
  8. 8.
    American Academy of Dermatology. New surgical techniques hold promise for treating vitiligo | aad.org [Internet]. 2015 [cited 26 February 2015]. Available from: https://www.aad.org/stories-and-news/news-releases/new-surgical-techniques-hold-promise-for-treating-vitiligo

Copyright information

© Springer International Publishing Switzerland 2017

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations